TABLE 3.
Multivariate analysis of the associations between clinicopathological parameters and metastasis‐free survival among patients with PSA persistence
| Variable | HR | 95% CI | P value |
|---|---|---|---|
| Treatment for PSA persistence | |||
| ADT | ref | ‐ | ‐ |
| RT | 1.67 | 0.67–4.16 | 0.27 |
| ADT plus RT | 0.37 | 0.15–0.93 | 0.034* |
| Clinical N‐stage | |||
| N0 | ref | ‐ | ‐ |
| N1 | 5.09 | 2.04–12.7 | 0.0005* |
| RP ISUP grade group | |||
| Group ≤III | ref | ‐ | ‐ |
| Group IV | 2.65 | 0.82–8.62 | 0.10 |
| Group V | 3.30 | 1.26–8.63 | 0.015* |
| Pathological T‐stage | |||
| T2/3a | ref | ‐ | ‐ |
| T3b | 1.94 | 0.96–3.92 | 0.066 |
| T4 | 11.6 | 3.33–40.2 | 0.0001* |
| Number of positive lymph nodes | |||
| 1 | ref | ‐ | ‐ |
| 2 | 0.90 | 0.42–1.95 | 0.79 |
| ≥3 | 1.19 | 0.58–2.41 | 0.64 |
Abbreviations: ADT, androgen deprivation therapy; CI, confidence interval; HR, hazard ratio; ISUP, International Society of Urological Pathology; PSA, prostate‐specific antigen; RP, radical prostatectomy; RT, radiotherapy.
*Statistically significant.